CompletedNCT02091388

Comparison of Two Long-Acting Risperidone Injections for Schizophrenia

About this title

Medication studyAges 18–65United States

The study in practice

Understand this study

Listed age limits: 18 years to 65 years.

Listed locations: Little Rock and 9 more locationsSee all locations and recruitment
Study phase: Phase 1

Study clarity

Study start dateSeptember 2014

Recruitment status: Completed
Enrollment listed in the registry: 108
Sponsor: Luye Pharma Group Ltd.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: United States
Age range: From 18 Years to 65 Years
Official registry ID: NCT02091388
Official title: Show the full official title
A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder

Completed

Little Rock · Long Beach · Orange

7 more locations

FAQ

Who is behind this study?

The study sponsor is Luye Pharma Group Ltd., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including LY03004 and Risperdal® Consta®.

Who was this study for?

Listed age limits: 18 years to 65 years.